



Bolt Biotherapeutics to Participate in Upcoming September Conferences

August 28, 2024

REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September:

- **Morgan Stanley 22nd Annual Global Healthcare Conference**
Fireside chat on Friday, Sept. 6, at 7:00 a.m. EDT (4:00 a.m. PDT)
- **H.C. Wainwright 26th Annual Global Investment Conference**
Company presentation available on Monday, Sept. 9, at 7:00am EDT (4:00 a.m. PDT)

A webcast of the presentations will be available on the Events and Presentations page of Bolt's website at www.boltbio.com. Archived replays will be available for 30 days following the event.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics' pipeline candidates are built on the Company's deep expertise in myeloid biology and cancer drug development. The Company's pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of seven different solid tumor types. BDC-4182 is supported by strong *in vitro* and *in vivo* data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit <https://www.boltbio.com/>.

Investor Relations and Media Contact:

Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com